Stefan Schürch

Stefan Schürch

Auto-generated profile, based on publicly available information

Stefan Schürch

Department of Chemistry and Biochemistry, University of Bern, Bern, Switzerland

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 March 2014 in Developmental & Comparative Immunology
Verified
Journal Article
Closed access
LKLucia Kuhn-Nentwig
Lucia Kuhn-Nentwig
LKLukas S. Kopp
Lukas S. Kopp
WNWolfgang Nentwig
Wolfgang Nentwig
BHBeat Haenni
Beat Haenni
KSKathrin Streitberger
Kathrin Streitberger
JSJohann Schaller
Johann Schaller

1 June 2021 in Carbohydrate Research
Verified
Journal Article
Open access
PBPia Bruni
Pia Bruni
SSStefan Schürch
Stefan Schürch
Tandem mass spectrometry has found widespread application as a powerful tool for the characterization of linear and branched oligosaccharides. Though the technique has been applied to the analysis of cyclic oligosaccharides as well, the underlying fragmentation mechanisms have hardly been investigated. This study focuses on the mechanistic aspects of the gas-phase dissociation of protonated β-cyclodextrins. Elucidation of the dissociation mechanisms is supported by tandem mass spectrometric experiments and by experiments on di- and trimethylated cyclodextrin derivatives. The fragmentation pathway comprises the linearization of the macrocyclic structure as the initial step of the decomposition, followed by the elimination of glucose subunits and the subsequent release of water and formaldehyde moieties from the glucose monomer and dimer fragment ions. Linearization of the macrocycle occurs due to proton-driven scission of the glycosidic bond adjacent to carbon atom C1 in conjunction with the formation of a new hydroxy group. The resulting ring-opened structure further decomposes in charge-independent processes forming either zwitterionic fragments, a 1,4-anhydroglucose moiety, or a new macrocyclic structure, that is lost as a neutral, and an oxonium ion. Since the hydroxy group formed at the ring-opening site can be regarded as the non-reducing end of the linearized structure, the fragment ion nomenclature commonly used for linear and branched oligosaccharides, which relies on the designation of a reducing and a non-reducing end, can also be applied to the description of fragment ions derived from cyclic structures.

28 November 2018 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
TBTais Basaco Bernabeu
Tais Basaco Bernabeu
SPStefanie Pektor
Stefanie Pektor
JBJosue M. Bermudez
Josue M. Bermudez
NMNiurka Meneses Moreno
Niurka Meneses Moreno
MHManfred Heller
Manfred Heller
MMMatthias Miederer
Matthias Miederer
Girentuximab (cG250) targets carbonic anhydrase IX (CAIX), a protein which is expressed on the surface of most renal cancer cells (RCCs). cG250 labeled with 177Lu has been used in clinical trials for radioimmunotherapy (RIT) of RCCs. In this work, an extensive characterization of the immunoconjugates allowed optimization of the labeling conditions with 177Lu while maintaining immunoreactivity of cG250, which was then investigated in in vitro and in vivo experiments. cG250 was conjugated with S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid (DOTA(SCN)) by using incubation times between 30 and 90 min and characterized by mass spectrometry. Immunoconjugates with five to ten DOTA(SCN) molecules per cG250 molecule were obtained. Conjugates with ratios less than six DOTA(SCN)/cG250 had higher in vitro antigen affinity, both pre- and postlabeling with 177Lu. Radiochemical stability increased, in the presence of sodium ascorbate, which prevents radiolysis. The immunoreactivity of the radiolabeled cG250 tested by specific binding to SK-RC-52 cells decreased when the DOTA content per conjugate increased. The in vivo tumor uptake was < 10% ID/g and independent of the total amount of protein in the range between 5 and 100 µg cG250 per animal. Low tumor uptake was found to be due to significant necrotic areas and heterogeneous CAIX expression. In addition, low vascularity indicated relatively poor accessibility of the CAIX target.

14 February 2013 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
BBBarbara Büchel
Barbara Büchel
JSJohanna Sistonen
Johanna Sistonen
Markus JoergerMarkus Joerger
Markus Joerger
YAYolanda Aebi
Yolanda Aebi
SSStefan Schürch
Stefan Schürch
Carlo LargiaderCarlo Largiader
Carlo Largiader
Background: Chemotherapies of solid tumors commonly include 5-fluorouracil (5-FU). With standard doses of 5-FU, substantial inter-patient variability has been observed in exposure levels and treatment response. Recently, improved outcomes in colorectal cancer patients due to pharmacokinetically guided 5-FU dosing were reported. We aimed at establishing a rapid and sensitive method for monitoring 5-FU plasma levels in cancer patients in our routine clinical practice. Methods: Performance of the Saladax My5-FU™ immunoassay was evaluated on the Roche Cobas® Integra 800 analyzer. Subsequently, 5-FU concentrations of 247 clinical plasma samples obtained with this assay were compared to the results obtained by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and other commonly used clinical analyzers (Olympus AU400, Roche Cobas c6000, and Thermo Fisher CDx90). Results: The My-FU assay was successfully validated on the Cobas Integra 800 analyzer in terms of linearity, precision, accuracy, recovery, interference, sample carryover, and dilution integrity. Method comparison between the Cobas Integra 800 and LC-MS/MS revealed a proportional bias of 7% towards higher values measured with the My5-FU assay. However, when the Cobas Integra 800 was compared to three other clinical analyzers in addition to LC-MS/MS including 50 samples representing the typical clinical range of 5-FU plasma concentrations, only a small proportional bias (≤1.6%) and a constant bias below the limit of detection was observed. Conclusions: The My5-FU assay demonstrated robust and highly comparable performance on different analyzers. Therefore, the assay is suitable for monitoring 5-FU plasma levels in routine clinical practice and may contribute to improved efficacy and safety of commonly used 5-FU-based chemotherapies.

7 May 2014 in Journal of the American Society for Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
ANAdrien Nyakas
Adrien Nyakas
RERahel P. Eberle
Rahel P. Eberle
SSSilvan R. Stucki
Silvan R. Stucki
SSStefan Schürch
Stefan Schürch